IRadimed Q3 2026 net income rises 17% to $6.51 million; revenue climbs 14% to $24.2 million
IRMD•IRadimed reported third-quarter 2026 revenue of $24.2 million, up 14% year over year, and diluted EPS of $0.51, up 17%. It narrowed full-year guidance and forecast fourth-quarter revenue of $25 million-$26.5 million and diluted EPS of $0.53-$0.57.
1. Quarterly results and outlook
IRadimed said its new 3870 MR IV pump launch drove record quarterly revenue, while bookings also reached a record. The company narrowed its 2026 revenue guidance to $91.6 million-$93.1 million and diluted EPS guidance to $1.90-$1.94.
